Rethinking Levetiracetam and Anticoagulation Safety
Levetiracetam, a common antiseizure medication frequently prescribed for its limited potential for drug interactions, may require more caution when paired with direct oral anticoagulants. Recent observational data suggests that patients taking this combination face a nearly twofold higher risk of thromboembolic events. This finding challenges the conventional belief that levetiracetam is a safe, inert choice for patients already undergoing anticoagulation therapy.
A retrospective study published August 17 in JAMA Neurology analyzed electronic health record data from more than 9000 adults with epilepsy who were receiving DOACs. The research utilized the TriNetX Global Collaborative Network, incorporating records from 165 healthcare organizations to track outcomes over time. The results indicated that those on levetiracetam had a hazard ratio of 1.98 for thromboembolic events compared to patients taking lamotrigine or lacosamide. Strong enzyme-inducing medications like carbamazepine were also linked to increased risks, though their relationship to bleeding events differed.
The Complexity of Drug Metabolism
Direct oral anticoagulants serve as a critical defense against stroke in patients with atrial fibrillation and for treating venous thromboembolism. Because many epilepsy patients also require these medications, the potential for drug-drug interactions is a constant clinical concern. Certain strong enzyme-inducing ASMs, such as phenytoin and phenobarbital, are known to boost CYP3A4 and P-glycoprotein activity. This biological change typically lowers the exposure of the body to the anticoagulant, thereby reducing its efficacy.
Researchers previously viewed levetiracetam as a nonenzyme-inducing alternative that avoids these common metabolic traps. The current study, however, shows that the risk profile might be more complicated than initial data suggested. While levetiracetam does not fit the profile of a classic enzyme inducer, the clinical signal for thromboembolism in this cohort was both strong and consistent. The investigators identified that 5.5% of patients in the levetiracetam group experienced thromboembolic events, a figure that stood in contrast to the 3.7% rate observed in the reference group taking lamotrigine or lacosamide.
Clinical Interpretations and Future Directions
Kai Michael Schubert, MD, PhD, of the University Hospital and University of Zurich, led the investigation and noted that the signal regarding levetiracetam was unexpected. He suggests that clinicians should treat this combination with active review rather than assuming safety. Still, the data does not confirm a direct causal link. Because levetiracetam lacks a clear mechanism for inducing relevant P-glycoprotein activity, the exact way this medication might contribute to thromboembolic risk remains unknown.
Independent experts urge clinical restraint. Sean Hennessy, PharmD, PhD, from the Perelman School of Medicine at the University of Pennsylvania, argues that these findings act more as a hypothesis to be tested than a reason to change medical practice immediately. He noted that if the interaction were purely pharmacokinetic, one would expect bleeding risks to drop alongside efficacy, which was not reflected in the outcomes. Michael Gelfand, MD, PhD, also from the University of Pennsylvania, pointed out that levetiracetam is often given to patients in acute settings, meaning the observed mortality rate might reflect the underlying severity of their illness rather than the drug itself. The medical community continues to monitor these patterns, but current guidance advises against reflexive changes in treatment for patients who are stable on their current regimen.